IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients

By WebmasterSeptember 17, 2024December 12th, 2024No Comments

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients

Previous PostWellsheet and Wolters Kluwer Collaborate to Integrate AI-Powered Clinical Workflows with UpToDate
Next PostThe pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes